Source:http://linkedlifedata.com/resource/pubmed/id/15261268
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
16
|
| pubmed:dateCreated |
2004-7-20
|
| pubmed:abstractText |
A series of novel, highly potent 2-carboxyindole-based factor Xa inhibitors is described. Structural requirements for neutral ligands, which bind in the S1 pocket of factor Xa were investigated with the 2-carboxyindole scaffold. This privileged fragment assembly approach yielded a set of equipotent, selective inhibitors with structurally diverse neutral P1 substituents.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0960-894X
|
| pubmed:author |
pubmed-author:BauerArminA,
pubmed-author:CzechJörgJ,
pubmed-author:DuddaAngelaA,
pubmed-author:EssrichMelanieM,
pubmed-author:LauxVolkerV,
pubmed-author:LorenzMartinM,
pubmed-author:MatterHansH,
pubmed-author:NazaréMarcM,
pubmed-author:RitterKurtK,
pubmed-author:SchreuderHermanH,
pubmed-author:UrmannMatthiasM,
pubmed-author:WehnerVolkmarV,
pubmed-author:WillDavid WDW
|
| pubmed:issnType |
Print
|
| pubmed:day |
16
|
| pubmed:volume |
14
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
4191-5
|
| pubmed:meshHeading | |
| pubmed:year |
2004
|
| pubmed:articleTitle |
Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents.
|
| pubmed:affiliation |
Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main, Germany. marc.nazare@aventis.com
|
| pubmed:publicationType |
Journal Article
|